Results of the trial, the only large randomized clinical trial to date to examine selenium supplementation alone in the prevention of CVD, appear in the April 15 issue of the American Journal of Epidemiology. Saverio Stranges, M.D., Ph.D., assistant professor of social and preventive medicine in the School of Public Health and Health Professions, University at Buffalo, is first author.
"Our results extend previous research based on smaller intervention trials focusing on cardiovascular risk factors," said Stranges. "Our findings are consistent with those from previous studies that have shown no beneficial effect of selenium supplementation in combination with other antioxidants on the primary prevention of cardiovascular disease."
Several antioxidants, vitamins C and E in particular, that were thought to play a role in preventing heart disease based on observational studies have turned out not to be protective in randomized clinical trials, and selenium now has joined this group.
The main findings of this report focus on the 1,004 participants in the study, conducted from 1983-96, who were free of cardiovascular disease when they were recruited. Participants came from seven dermatology clinics in low selenium areas of the eastern United States: Augusta and Macon, Ga.; Columbia, S.C.; Miami, Fla.; Wilson and Greenville, N. C.; and Newington, Conn.
Enrollees were assigned randomly to take a tablet containing 200 micrograms of selenium daily or a placebo. Information on sociodemographics, he
Source:University at Buffalo